OTTAWA, ON – Avivagen Inc., a life sciences company commercializing products intended to replace the antibiotics added to livestock feeds, has launched a new project to explore the potential application of its OxC-beta™ technology in human health.
With the help of the National Research Council of Canada (NRC), the company plans to evaluate the efficacy of OxC-beta in an established research model of a yet to be announced human infectious disease. As part of the project, work will be conducted by NRC experts at its facilities based upon a jointly developed protocol and is expected to be completed in 2017.
The OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth.
“We are pleased to be working with NRC on this project to establish a proof-of-concept for use of OxC-beta for a first potential human application – likely as a preventative intervention or as part of a therapeutic regimen,” Dr. James (Jamie) Nickerson, Avivagen’s director of Product Validation, commented. He adds that OxC-beta has demonstrated safety and effectiveness across more than a dozen livestock trials and those results suggest it may also prove to be important to human health and well-being.
“The results of this project should help to provide such evidence,” he said.
“Antibiotic drug resistance in bacteria is a major concern that could affect the health of Canadians as previously curable infections may become untreatable and spread through the community,” said Dr. Lakshmi Krishnan, program leader in Human Health Therapeutics at the National Research Council of Canada. “We have a long-standing expertise in infectious disease research and are pleased to collaborate with Avivagen on this innovative project which will evaluate the potential of OxC-beta to provide additional effective human health treatments.”
Avivagen says it is not disclosing the specific disease target at this time to help ensure the patentability of this potential new application for the OxC-beta™ technology. However, the company does say that the disease target is one of the top 18 urgent, serious or concerning drug-resistance threats listed by the U.S. Centers for Disease Control.
Avivagen intends to summarize the results of the project following its completion and after the filing of any patent application supported by a positive proof-of-concept.